Congress (U.S. Legislature)
Vir Biotechnology Reports Positive Update on Hepatitis Delta Combination and Monotherapy Treatments
Vir Biotechnology, Hepatitis Delta, Combination Therapy, Monotherapy, Clinical Trial, EASL Congress
Legislators Profit from Bill Restricting Chinese Biotech Firms
Congress, stock trading, China biotech ban, financial gain, legislative influence, conflict of interest.